Project Grant R01AI189583
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$622K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen (HBsAg) clearance. The $814,790 grant, awarded on November 20, 2024 with a completion date of October 31, 2029, will enable a collaborative effort between researchers at the University of California, San Francisco...
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to advance understanding of virus-host interactions and develop curative therapies for chronic hepatitis B virus (HBV) infections. The research aims to explore the mechanisms by which interferon alpha treatment can lead to HBV cure, investigate the role of HBV genotypes and mutations, and leverage advances in cell culture...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $598,764 to The Trustees of Princeton University to conduct research aimed at targeting the hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) to combat chronic HBV infection, particularly in the context of HIV coinfection. The key activities include:
Determining whether transient genetic disruption of host factors...
This $2,225,199 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to advance understanding of the immune responses underlying hepatitis B virus (HBV) functional cure. The primary objectives are to:
Define the functions and molecular signatures of HBV-specific CD4 T cells that are important for viral suppression versus functional cure.
Characterize HBV-specific humoral...
The University of Southern California (USC) received a $249,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on the host response to Hepatitis Delta Virus (HDV) infection. The grant, effective from April 1, 2025 to March 31, 2027, aims to elucidate the mechanisms by which HDV exploits the host's interferon-stimulated gene (ISG) induction pathway to sustain its viral lifecycle,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Regents of the University of California, San Francisco (UCSF). The award, titled "HEPATIC PRIMING OF CD4+ T CELLS DIRECTS EFFECTIVE HEPATITIS B VIRUS IMMUNITY", will provide $234,735.00 in funding from August 8, 2024 through March 14, 2027. The project aims to investigate the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $730,270 Project Grant (CFDA 93.855) to The Johns Hopkins University to research mechanisms underlying hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional silencing in individuals with HBV mono-infection versus HBV/HIV co-infection. The 5-year project aims to quantify intrahepatic viral DNA/RNA, characterize host genes regulating HBV transcription, and analyze epigenetic modifications of...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $788,208 to Rockefeller University to develop a mouse model susceptible to chronic hepatitis B virus (HBV) infection. The goal is to identify host and viral determinants that can allow HBV to establish its covalently closed circular DNA (cccDNA) within murine hepatocytes, which is a key barrier to infection in mouse models. The project aims...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $664,837 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California (USC) Department of Contracts and Grants Division. This 1-year grant, effective from September 1, 2024 to August 31, 2025, will fund research to identify newborns with in-utero SARS-CoV-2 infection and assess associated immunologic factors and clinical outcomes. Key objectives...